Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 37.76%.

  • Regenerative Medical Technology's EBIT Margin fell 397500.0% to 37.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.58%, marking a year-over-year increase of 99500.0%. This contributed to the annual value of 1.98% for FY2024, which is 316500.0% up from last year.
  • Latest data reveals that Regenerative Medical Technology reported EBIT Margin of 37.76% as of Q3 2025, which was down 397500.0% from 25.43% recorded in Q2 2025.
  • Regenerative Medical Technology's 5-year EBIT Margin high stood at 25.19% for Q4 2024, and its period low was 5462.49% during Q3 2021.
  • Over the past 5 years, Regenerative Medical Technology's median EBIT Margin value was 37.76% (recorded in 2025), while the average stood at 617.31%.
  • Per our database at Business Quant, Regenerative Medical Technology's EBIT Margin tumbled by -50663700bps in 2021 and then skyrocketed by 54185200bps in 2022.
  • Regenerative Medical Technology's EBIT Margin (Quarter) stood at 196.56% in 2021, then tumbled by -121bps to 433.93% in 2022, then surged by 95bps to 21.95% in 2023, then soared by 215bps to 25.19% in 2024, then plummeted by -250bps to 37.76% in 2025.
  • Its EBIT Margin stands at 37.76% for Q3 2025, versus 25.43% for Q2 2025 and 9.89% for Q1 2025.